Please note the following information which has been provided by Mylan in relation to the supply of the above mentioned product.

There are supply disruptions with Mylan’s Amisulpride product Sulprix 400mg (PHARMACODE 2500159) that are not expected to be resolved until early 2019. This is a low volume product with less than 200 units consumed monthly across New Zealand.


We apologise for any inconvenience caused and recommend that patients are provided with equivalent dose of Amisulpride using Sulprix 200mg tablets (PHARMACODE 2500140) during this supply disruption to the 400mg tablets.


Given the pharmacokinetic properties of Amisulpride (50% absolute bioavailability, negligible first pass effect, linear pharmacokinetics, absorption unaffected by food, inactive metabolites), demonstrated bioequivalence (rate and extent of absorption of Sulprix 400 mg tablets), qualitatively direct scaled formulations shared by all Sulprix strengths (50, 100, 200 and 400 mg tablets) and similarity in the release rate profiles of all strengths including the fact that the drug has a wide therapeutic index we see no reason for pharmacokinetic differences when Sulprix 400mg tablet is substituted with Sulprix 200mg (Pharmacode- 2500140)  x 2 tablets.

We thank you in anticipation of your ongoing support.

About The Author